Dr. Wierda Discusses Watchful Waiting in CLL

William G. Wierda, MD, PhD
Published: Wednesday, Mar 14, 2012

William G. Wierda, MD, PhD, associate professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, explains that the standard initial treatment for patients with asymptomatic chronic lymphocytic leukemia (CLL) is watchful waiting.

Clinical trials have not illuminated a clear improvement in outcomes linked to providing earlier treatments for CLL, when compared to observation alone. In general, the risks of receiving a treatment outweighed the potential benefits. As a result, the first-line therapy is generally administered following the development of certain indications, such as bone marrow failure, which is reflected by low hemoglobin or platelets counts.

Wierda notes that watchful waiting has been the first step in CLL treatment for many years and will continue to be the best place to start for many patients, until another option becomes available.

William G. Wierda, MD, PhD, associate professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, explains that the standard initial treatment for patients with asymptomatic chronic lymphocytic leukemia (CLL) is watchful waiting.

Clinical trials have not illuminated a clear improvement in outcomes linked to providing earlier treatments for CLL, when compared to observation alone. In general, the risks of receiving a treatment outweighed the potential benefits. As a result, the first-line therapy is generally administered following the development of certain indications, such as bone marrow failure, which is reflected by low hemoglobin or platelets counts.

Wierda notes that watchful waiting has been the first step in CLL treatment for many years and will continue to be the best place to start for many patients, until another option becomes available.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions and New Answers to Optimize OutcomesOct 31, 20182.0
Hematology Briefings™: Advancing Care and Improving Outcomes for Patients With Pyruvate Kinase DeficiencyOct 31, 20181.0
Publication Bottom Border
Border Publication
x